AbbVie Inc., and Tentarix Biotherapeutics announced a multi-year collaboration focused on the discovery and development of conditionally-active, multi-specific biologic candidates in oncology and immunology....
AbbVie, announced that it has completed its acquisition of ImmunoGen. With the completion of the acquisition, ImmunoGen is now part of AbbVie.
"Together with ImmunoGen,...
AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved EPKINLY, as the first and only T-cell engaging bispecific antibody for the...
AbbVie announced key results from a phase 2 study of upadacitinib given as monotherapy, or in combination therapy (ABBV-599) with elsubrutinib, a kinase inhibitor...
AbbVie announced topline results from a Phase 2 study of upadacitinib given alone or as combination therapy (ABBV-599) with a Bruton's Tyrosine Kinase inhibitor (elsubrutinib,...
